Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Cash from Investing Activities (2018 - 2025)

Historic Cash from Investing Activities for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to $22.0 million.

  • Neurogene's Cash from Investing Activities rose 17591.66% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$118.2 million, marking a year-over-year decrease of 381180.53%. This contributed to the annual value of -$125.3 million for FY2024, which is 58859.46% down from last year.
  • As of Q3 2025, Neurogene's Cash from Investing Activities stood at $22.0 million, which was up 17591.66% from $7.4 million recorded in Q2 2025.
  • Neurogene's 5-year Cash from Investing Activities high stood at $29.9 million for Q1 2024, and its period low was -$102.6 million during Q4 2024.
  • For the 3-year period, Neurogene's Cash from Investing Activities averaged around -$10.5 million, with its median value being -$82000.0 (2023).
  • Over the last 5 years, Neurogene's Cash from Investing Activities had its largest YoY gain of 10332413.79% in 2024, and its largest YoY loss of 3522439.02% in 2024.
  • Quarter analysis of 3 years shows Neurogene's Cash from Investing Activities stood at $25.8 million in 2023, then tumbled by 497.27% to -$102.6 million in 2024, then soared by 121.43% to $22.0 million in 2025.
  • Its Cash from Investing Activities was $22.0 million in Q3 2025, compared to $7.4 million in Q2 2025 and -$45.0 million in Q1 2025.